Tcgx Acquisition Signs $361M M&A Deal with TriGemX Bio, Inc.
TCGX Acquisition Corp. (SPAC) has entered into a definitive business combination agreement with TriGemX Bio, Inc. at a pre-money equity value of $361 million. The transaction includes a concurrent $160 million PIPE financing and is expected to provide approximately $246 million in gross proceeds to fund Phase 3 development of elismetrep for migraine. Upon closing, expected in Q1 2027, the combined company will be named TriGemX Bio, Inc. and trade on Nasdaq under the ticker TGEM.
- Value
- $361M
- Counterparty
- TriGemX Bio, Inc.